RxDoctor Payments Data

Francis Wilson, MD

Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1669537890

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,200 of the $1,236 with a category attached, or 97.0%. Boston Scientific accounts for 97.0% of it on its own, with 1 other manufacturer making up the rest.

$1,236in general payments, 2019–2025

Across 2 payments — averaging $618.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Amgen$36
$413,350in research payments, 2019–2025

Across 2 payments — averaging $206,675 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$291K
  • AstraZeneca$122K

What the payments were for

  • Speaking & faculty fees$1,20097%
  • Food & beverage$363%

General payments by program year

21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific1$1,200
Amgen1$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,236 in reported general payments places this provider in the 55th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut

Medicare billing

Part B allowed, 2024
$7,541
Medicare patients
25
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →